Recombinant GM-CSF is used in clinical practice for the treatment of a wide range of hematopoietic diseases, including chemotherapy-induced neutropenia, and it is also being investigated for the treatment of several other diseases (neurodegenerative, autoimmune, cancer, wound healing, etc.). The gene discussed is CSF2; the disease is neutropenia.